These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10677750)

  • 1. Criteria of Chagas disease cure.
    Cançado JR
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():331-5. PubMed ID: 10677750
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of a recombinant Trypanosoma cruzi protein antigen to monitor cure of Chagas disease.
    Guevara AG; Taibi A; Alava J; Guderian RH; Ouaissi A
    Trans R Soc Trop Med Hyg; 1995; 89(4):447-8. PubMed ID: 7570896
    [No Abstract]   [Full Text] [Related]  

  • 3. Summaries for patients. Long-term outcomes of treating nonacute Chagas disease with benznidazole.
    Ann Intern Med; 2006 May; 144(10):I32. PubMed ID: 16702585
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of immunosuppression and benzonidazole on Trypanosoma cruzi parasitism during experimental acute Chagas' disease.
    Okumura M; Mester M; Iriya K; Amato Neto V; Gama-Rodrigues J
    Transplant Proc; 1994 Jun; 26(3):1587-9. PubMed ID: 8030049
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease.
    Ghobadifar MA; Kalani N; Gitiforouz M; Mosallanejad Z
    Rev Soc Bras Med Trop; 2014; 47(5):669. PubMed ID: 25467275
    [No Abstract]   [Full Text] [Related]  

  • 6. Authors' reply: Vitamins in the treatment of chronic Chagas disease: adjuvant antiparasitary or antioxidant therapy?
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2014; 47(5):670-1. PubMed ID: 25467276
    [No Abstract]   [Full Text] [Related]  

  • 7. Recognition for Chagas disease.
    Burki T
    Lancet Infect Dis; 2019 Jul; 19(7):699. PubMed ID: 31250822
    [No Abstract]   [Full Text] [Related]  

  • 8. A flagellated protozoa in the urine: other than Trichomonas.
    Poloni JA; Moraes CM; Seelig DC; Rotta LN; Pasqualotto AC
    Kidney Int; 2014 Jun; 85(6):1476. PubMed ID: 24875560
    [No Abstract]   [Full Text] [Related]  

  • 9. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
    Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
    PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shift of excretory-secretory immunogens of Trypanosoma cruzi during human Chagas' disease.
    Jazín EE; Luquetti AO; Rassi A; Frasch AC
    Infect Immun; 1991 Jun; 59(6):2189-91. PubMed ID: 1903775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New advances in the management of a long-neglected disease.
    Urbina JA
    Clin Infect Dis; 2009 Dec; 49(11):1685-7. PubMed ID: 19877968
    [No Abstract]   [Full Text] [Related]  

  • 12. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 13. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study.
    Galvao LM; Nunes RM; Cançado JR; Brener Z; Krettli AU
    Trans R Soc Trop Med Hyg; 1993; 87(2):220-3. PubMed ID: 8337734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study.
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2013; 46(6):776-8. PubMed ID: 24474023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitrypanosomal therapy for chronic Chagas' disease.
    Garcia-Bournissen F; Altcheh J
    N Engl J Med; 2011 Sep; 365(13):1258; author reply 1259. PubMed ID: 21991908
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitrypanosomal therapy for chronic Chagas' disease.
    Bestetti RB; Cardinalli-Neto A
    N Engl J Med; 2011 Sep; 365(13):1258-9; author reply 1259. PubMed ID: 21991909
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.
    Viotti R; Vigliano C; Armenti H; Segura E
    Am Heart J; 1994 Jan; 127(1):151-62. PubMed ID: 8273735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of the polymerase chain reaction for monitoring cure of mice infected with different Trypanosoma cruzi clonal genotypes following treatment with benznidazole.
    Miyamoto CT; Gomes ML; Marangon AV; de Araújo SM; Bahia MT; Martins-Filho OA; de Lana M; de Ornelas Toledo MJ
    Exp Parasitol; 2008 Sep; 120(1):45-9. PubMed ID: 18533149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic Chagas' disease: effects of treatment nn the levels of antibodies to crude and partially purified Trypanosoma cruzi antigens].
    Moretti E; Cervetta L; Basso B; Castro I; Santamarina N
    Bol Chil Parasitol; 1998; 53(1-2):3-9. PubMed ID: 9830716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.